Sertraline Treatment of Generalized Social Phobia: A 20-Week, Double-Blind, Placebo-Controlled Study

Ameringen, M.A. Van; Lane, Roger; Walker, John R.; Bowen, Rudy; Chokka, Pratap; Goldner, Elliot M.; Johnston, David G.; Lavallée, Yvon-Jacques; Nandy, Saibal; Pecknold, John C.; Hadrava, Vratislav; Swinson, Richard P.

doi:10.1176/appi.ajp.158.2.275

Cited by 169 publications

(103 citation statements)

References 27 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Relapse rates were significantly lower in the paroxetine group (Stein et al 2002b)(A). Á Sertraline has been shown to be effective in DBPC studies: (Blomhoff et al 2001;Katzelnick et al 1995;van Ameringen et al 2001). The efficacy has also been shown in the long term.…”

Section: Summary Of Recommendations For the Treatment Of Gadmentioning

confidence: 99%

“…The efficacy has also been shown in the long term. In one 24-week DBPC study (Blomhoff et al 2001) and a 24-week relapse prevention study following a 20-week DBPC study (van Ameringen et al 2001), the efficacy of sertraline could be demonstrated (A). Á Citalopram was effective in one DBPC study (Furmark et al 2005)(B).…”

Section: Summary Of Recommendations For the Treatment Of Gadmentioning

confidence: 99%

See 1 more Smart Citation

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

712

410

View full text Add to dashboard Cite

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo-or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/ SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

show abstract

Section: Summary Of Recommendations For the Treatment Of Gadmentioning

confidence: 99%

Section: Summary Of Recommendations For the Treatment Of Gadmentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

712

410

View full text Add to dashboard Cite

show abstract

“…However, a high percentage of SAD patients fail to respond to the available treatment options, or achieve only partial remission of symptoms, with antidepressants providing the best response rates Baldwin et al, 1999;Van Ameringen et al, 2001). Given the high prevalence and unsatisfactory treatment options for SAD, a better understanding of the etiology and underlying neurobiological mechanisms of social fear, particularly extinction of social fear, is urgently needed.…”

Section: Introductionmentioning

confidence: 99%

Social Fear Conditioning: A Novel and Specific Animal Model to Study Social Anxiety Disorder

Toth

Neumann

Slattery

2012

Neuropsychopharmacol

125

View full text Add to dashboard Cite

Social anxiety disorder (SAD) is a major health concern with high lifetime prevalence. The current medication is rather unspecific and, despite considerable efforts, its efficacy is still unsatisfactory. However, there are no appropriate and specific animal models available to study the underlying etiology of the disorder. Therefore, we aimed to establish a model of specific social fear in mice and use this social fear conditioning (SFC) model to assess the therapeutic efficacy of the benzodiazepine diazepam and of the antidepressant paroxetine; treatments currently used for SAD patients. We show that by administering electric foot shocks (2-5, 1 s, 0.7 mA) during the investigation of a con-specific, the investigation of unfamiliar con-specifics was reduced for both the short-and long-term, indicating lasting social fear. The induced fear was specific to social stimuli and did not lead to other behavioral alterations, such as fear of novelty, general anxiety, depression, and impaired locomotion. We show that social fear was dose-dependently reversed by acute diazepam, at doses that were not anxiolytic in a non-social context, such as the elevated plus maze. Finally, we show that chronic paroxetine treatment reversed social fear. All in all, we demonstrated robust social fear after exposure to SFC in mice, which was reversed with both acute benzodiazepine and chronic antidepressant treatment. We propose the SFC model as an appropriate animal model to identify the underlying etiology of SAD and possible novel treatment approaches.

show abstract

“…Van Amering et al 25 evaluated sertraline vs. placebo in 204 generalized SAD patients for a 20-week doubleblind study. The dosing was flexible up to a maximum of 2000mg/day.…”

Section: Serotonin-specific Reuptake Inhibitors (Ssris)mentioning

confidence: 99%

Antidepressants in social anxiety disorder

Nardi

2001

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

-Social anxiety disorder (SAD) is a marked and persistent fear of doing almost everything in front of people due to concerns about being judge by others. An up-to-date review is needed in order to reach a practical judgement of all psychopharmacological data. Case reports, open and double-blind trials with SAD were described and commented upon from a clinical point of view. The MEDLINE system was searched from 1975 to 2001. The references from the selected papers were also used as a source. MAOIs (fenelzine, tranylcypromine), reversible monoamino oxidase-A inhibitors (moclobemide, brofaromine), SSRIs (paroxetine, sertraline, fluoxetine, fluvoxamine) and some other antidepressants (venlafaxine, nefazodone) have proven effective in several studies with various methodologies. The MAOIs have more serious adverse effects and the SSRIs have the best tolerance. SSRIs are efficacious and the first choice of treatment.KEY WORDS: social anxiety disorder, social phobia, pharmacologic treatment. Antidepressivos no transtorno de ansiedade socialRESUMO -A fobia social é o medo acentuado e persistente patológico de comer, beber, tremer, enrubescer, falar, escrever, enfim, de agir de forma ridícula ou inadequada na presença de outras pessoas. Muitos estudos clínicos têm sido conduzidos com o objetivo de se obter um tratamento eficaz. É necessária uma revisão atualizada para alcançar um julgamento clínico de todos os dados com antidepressivos. O sistema MEDLINE foi pesquisado no período de 1975 a 2001. As referências dos artigos consultados também foram utilizadas com fonte. Antidepressivos inibidores da monoamino oxidase (IMAO) (fenelzine, tanilcipromina), inibidores reversíveis da monoamino oxidase tipo A (RIMA) (moclobemida, brofaromina), antidepressivos inibidores seletivos de serotonina (ISRS) (paroxetina, sertralina, fluoxetina, fluvoxamina) e alguns outros (venlafaxina, nefazodone) têm demonstrado eficácia em inúmeros estudos com diferentes metodologias. Os ISRS são o grupo mais estudado com metodologia duplo-cega, com melhores resultados e com boa tolerância, sendo a primeira escolha no tratamento. PALAVRAS-CHAVE: fobia social, transtorno de ansiedade social, tratamento farmacológico.

show abstract

Sertraline Treatment of Generalized Social Phobia: A 20-Week, Double-Blind, Placebo-Controlled Study

Abstract: Sertraline is an effective treatment for patients with generalized social phobia.

Cited by 169 publications

References 27 publications

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Social Fear Conditioning: A Novel and Specific Animal Model to Study Social Anxiety Disorder

Antidepressants in social anxiety disorder

Contact Info

Product

Resources

About